Bicycle Therapeutics (NASDAQ:BCYC) Receives “Equal Weight” Rating from Stephens

Bicycle Therapeutics (NASDAQ:BCYC)‘s stock had its “equal weight” rating reiterated by investment analysts at Stephens in a report issued on Wednesday,Benzinga reports. They presently have a $15.00 price objective on the stock. Stephens’ price target would indicate a potential upside of 13.38% from the company’s current price.

A number of other research analysts also recently weighed in on BCYC. JMP Securities reduced their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of Bicycle Therapeutics in a research report on Monday, January 13th. B. Riley decreased their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of Bicycle Therapeutics in a report on Monday, January 13th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.25.

Bicycle Therapeutics Stock Up 0.2 %

Shares of NASDAQ BCYC opened at $13.23 on Wednesday. The company has a market capitalization of $913.53 million, a PE ratio of -4.02 and a beta of 0.92. The stock’s 50 day moving average price is $16.92 and its 200-day moving average price is $21.34. Bicycle Therapeutics has a twelve month low of $12.17 and a twelve month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The firm had revenue of $2.68 million during the quarter, compared to the consensus estimate of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The business’s revenue for the quarter was down 50.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.26) EPS. As a group, research analysts expect that Bicycle Therapeutics will post -3.05 EPS for the current fiscal year.

Insider Transactions at Bicycle Therapeutics

In related news, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $25.11, for a total value of $157,088.16. Following the sale, the chief accounting officer now owns 19,241 shares in the company, valued at approximately $483,141.51. This trade represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Alistair Milnes sold 4,578 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $64,504.02. Following the transaction, the chief operating officer now owns 100,724 shares of the company’s stock, valued at approximately $1,419,201.16. The trade was a 4.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,933 shares of company stock valued at $549,501. 8.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC purchased a new stake in Bicycle Therapeutics in the third quarter valued at approximately $3,406,000. The Manufacturers Life Insurance Company raised its position in shares of Bicycle Therapeutics by 33.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after buying an additional 32,313 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of Bicycle Therapeutics during the 3rd quarter worth $10,028,000. State Street Corp grew its position in Bicycle Therapeutics by 233.5% in the third quarter. State Street Corp now owns 86,271 shares of the company’s stock worth $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Finally, Perceptive Advisors LLC bought a new position in Bicycle Therapeutics in the second quarter valued at $11,577,000. Hedge funds and other institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.